Moderators of fluoxetine treatment response for children and adolescents with comorbid depression and substance use disorders
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Our recent 8-week, randomized, placebo-controlled trial of fluoxetine in adolescents (ages 12–17 years) with comorbid depression and substance use disorder (SUD) did not detect a significant antidepressant treatment effect. The purpose of this secondary analysis was to explore moderators of the effect of fluoxetine in this sample. Static moderators measured at baseline were depression chronicity and hopelessness severity; time-varying moderators measured at baseline and weekly during the 8-week trial period were alcohol and marijuana use severity. Treatment effects on depression outcomes were examined among moderating subgroups in random effects regression models. Subjects assigned to fluoxetine treatment with chronic depression at baseline (p = .04) or no more than moderate alcohol use during the trial (p = .04) showed significantly greater decline in depression symptoms in comparison to placebo-assigned subgroups. The current analysis suggests that youth with chronic depression and no more than moderate alcohol consumption are likely to respond better to treatment with fluoxetine compared with placebo than youth with transient depression and heavy alcohol use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Relationship between hopelessness and ultimate suicide: a replication with psychiatric outpatients
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.2.190 · Cited by 1,120
Bridge, J. A., Birmaher, B., Iyengar, S., Barbe, R. P., & Brent, D. A. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020247 · Cited by 256
Psychiatric disorders and attempted suicide among adolescents with substance use disorders
Kelly, T. M., Cornelius, J. R., & Clark, D. B. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2003.10.004 · Cited by 123
Tuisku, V., Pelkonen, M., Karlsson, L., Kiviruusu, O., Holi, M., Ruuttu, T., Punamäki, R.-L., & Marttunen, M. (2006) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-005-0522-3 · Cited by 78 · cited 1×
“Adolescent-onset depression is a common and serious psychiatric condition associated with substantive psychosocial dysfunction, including increased risk for suicide attempts and completed suicide (Curry et al., 2006; Fordwood, Asarnow, Huizar, & Reise, 2007; Tuisku et al., 2006).”
Background
Cited by
Pharmacotherapies for cannabis dependence.
Marshall, K., Gowing, L., Ali, R., & Le Foll, B. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub2 · Cited by 156
Pharmacotherapies for cannabis dependence
Nielsen, S., Gowing, L., Sabioni, P., & Le Foll, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub3 · Cited by 96
Treating Mental Health and Substance Use Disorders in Adolescents: What Is on the Menu?
Brewer, S., Godley, M. D., & Hulvershorn, L. A. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0755-0 · Cited by 79
Rohden, A. I., Benchaya, M. C., Camargo, R. S., Moreira, T. D. C., Barros, H. M. T., & Ferigolo, M. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.03.017 · Cited by 35
Babowitch, J. D., & Antshel, K. M. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.04.018 · Cited by 30
Metadata
- Authors
- Hirschtritt, M. E., Pagano, M. E., Christian, K. M., McNamara, N. K., Stansbrey, R. J., Lingler, J., Faber, J. E., Demeter, C. A., Bedoya, D., & Findling, R. L.
- Venue
- Journal of Substance Abuse Treatment
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 42
- Issue
- 4
- Pages
- 366-372
- ISSN
- 0740-5472 (ISSN-L)
- OpenAlex
- W2127348920
- Cited by
- 17
- References
- 5
- FWCI
- 1.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.